blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2828250

EP2828250 - QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.01.2022
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  05.02.2021
FormerGrant of patent is intended
Status updated on  20.09.2020
FormerExamination is in progress
Status updated on  17.02.2017
Most recent event   Tooltip06.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 09.10.2024 [2024/41]
Applicant(s)For all designated states
Imperial College Innovations Limited
Level 1 Faculty Building
c/o Imperial College
Exhibition Road
London SW7 2AZ / GB
For all designated states
Emory University
1599 Clifton Rd. NE 4th Floor
Atlanta, GA 30322 / US
[2019/50]
Former [2015/05]For all designated states
Imperial Innovations Limited
52 Princes Gate Exhibition Road
London SW7 2PG / GB
For all designated states
Emory University
1599 Clifton Rd. NE 4th Floor
Atlanta, GA 30322 / US
Inventor(s)01 / BROWN, Robert
c/o Imperial College London
Exhibition Road
South Kensington
London SW7 2AZ / GB
02 / FUCHTER, Matthew John
c/o Imperial College London
Exhibition Road
South Kensington
London SW7 2AZ / GB
03 / CHAPMAN-ROTHE, Nadine
c/o Imperial College London
Exhibition Road
South Kensington
London SW7 2AZ / GB
04 / SRIMONGKOLPITHAK, Nitipol
Flat 4
71 Queen's Gate
London SW7 5JT / GB
05 / CARON, Joachim
74 Comeragh Road
London W14 9HR / GB
06 / SNYDER, James P
1085 Rosedale Drive
Atlanta, Georgia 30306 / US
07 / GANESH, Thota
3360 Archgate Court
Alpharetta
Atlanta, Georgia 30004 / US
08 / LIU, Jin
831 Highland Lake Circle
Decatur
Atlanta, Georgia 30033 / US
09 / SUN, Aiming
1624 Johnson Road
Atlanta, Georgia 30306 / US
 [2021/10]
Former [2015/05]01 / BROWN, Robert
c/o Imperial College London
Exhibition Road
South Kensington
London SW7 2AZ / GB
02 / FUCHTER, Matthew John
c/o Imperial College London
Exhibition Road
South Kensington
London SW7 2AZ / GB
03 / CHAPMAN-ROTHE, Nadine
c/o Imperial College London
Exhibition Road
South Kensington
London SW7 2AZ / GB
04 / SRIMONGKOLPITHAK, Nitipol
Flat 4
71 Queen's Gate
London SW7 5JT / GB
05 / CARON, Joachim
74 Comeragh Road
London W14 9HR / GB
06 / SYNDER, James
1085 Rosedale Drive
Atlanta, Georgia 30306 / US
07 / GANESH, Thota
3360 Archgate Court
Alpharetta
Atlanta, Georgia 30004 / US
08 / LIU, Jin
831 Highland Lake Circle
Decatur
Atlanta, Georgia 30033 / US
09 / SUN, Aiming
1624 Johnson Road
Atlanta, Georgia 30306 / US
Representative(s)Abel & Imray LLP
Westpoint Building
James Street West
Bath BA1 2DA / GB
[N/P]
Former [2021/10]Abel & Imray
Westpoint Building
James Street West
Bath BA1 2DA / GB
Former [2015/05]Brady, Paul Andrew, et al
Abel & Imray
20 Red Lion Street
London WC1R 4PQ / GB
Application number, filing date13721004.319.03.2013
[2021/10]
WO2013GB50689
Priority number, dateUS201261612694P19.03.2012         Original published format: US 201261612694 P
[2015/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013140148
Date:26.09.2013
Language:EN
[2013/39]
Type: A1 Application with search report 
No.:EP2828250
Date:28.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 26.09.2013 takes the place of the publication of the European patent application.
[2015/05]
Type: B1 Patent specification 
No.:EP2828250
Date:10.03.2021
Language:EN
[2021/10]
Search report(s)International search report - published on:EP26.09.2013
ClassificationIPC:C07D401/14, C07D405/14, C07D401/12, C07D239/95, C07D491/056, A61K31/517, A61P35/00, A61P31/18, A61P25/28
[2015/05]
CPC:
C07D239/95 (EP,US); A61K31/517 (EP,US); A61K31/519 (EP,US);
A61K31/5377 (EP,US); A61K31/55 (EP,US); A61K31/551 (EP,US);
A61P25/28 (EP); A61P31/18 (EP); A61P35/00 (EP);
C07D401/04 (EP,US); C07D401/12 (EP,US); C07D401/14 (EP,US);
C07D403/12 (EP,US); C07D405/14 (EP,US); C07D491/056 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/05]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:CHINAZOLIN-VERBINDUNGEN UND IHRE THERAPEUTISCHE VERWENDUNG[2020/31]
English:QUINAZOLINE COMPOUNDS AND THEIR USE IN THERAPY[2015/05]
French:COMPOSES DE QUINAZOLINE ET LEUR APPLICATION THERAPEUTQUE[2020/31]
Former [2015/05]CHINAZOLINVERBINDUNGEN UND DEREN THERAPEUTISCHE VERWENDUNG
Former [2015/05]COMPOSÉS DE QUINAZOLINE ET LEUR UTILISATION THÉRAPEUTIQUE
Entry into regional phase17.10.2014National basic fee paid 
17.10.2014Designation fee(s) paid 
17.10.2014Examination fee paid 
Examination procedure17.10.2014Examination requested  [2015/05]
21.09.2015Amendment by applicant (claims and/or description)
21.02.2017Despatch of a communication from the examining division (Time limit: M06)
31.08.2017Reply to a communication from the examining division
07.02.2018Despatch of a communication from the examining division (Time limit: M06)
16.08.2018Reply to a communication from the examining division
24.09.2018Despatch of a communication from the examining division (Time limit: M06)
02.05.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
12.07.2019Reply to a communication from the examining division
02.01.2020Despatch of a communication from the examining division (Time limit: M06)
16.06.2020Reply to a communication from the examining division
21.09.2020Communication of intention to grant the patent
01.02.2021Fee for grant paid
01.02.2021Fee for publishing/printing paid
01.02.2021Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.02.2017
Opposition(s)13.12.2021No opposition filed within time limit [2022/07]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
12.07.2019Request for further processing filed
12.07.2019Full payment received (date of receipt of payment)
Request granted
25.07.2019Decision despatched
Fees paidRenewal fee
30.03.2015Renewal fee patent year 03
30.03.2016Renewal fee patent year 04
12.09.2017Renewal fee patent year 05
28.03.2018Renewal fee patent year 06
28.03.2019Renewal fee patent year 07
18.03.2020Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.03.201705   M06   Fee paid on   12.09.2017
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.03.2013
AL10.03.2021
AT10.03.2021
CY10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
MK10.03.2021
MT10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
[2024/41]
Former [2024/22]HU19.03.2013
AL10.03.2021
AT10.03.2021
CY10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
MK10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2023/30]HU19.03.2013
AL10.03.2021
AT10.03.2021
CY10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2023/27]HU19.03.2013
AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2022/34]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
BE31.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2022/23]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2022/11]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SI10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
Former [2022/10]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
CH31.03.2021
LI31.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
Former [2022/08]AL10.03.2021
AT10.03.2021
CZ10.03.2021
DK10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
LU19.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2022/07]AL10.03.2021
AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
MC10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
IE19.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2021/52]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
PL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2021/51]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
IS10.07.2021
PT12.07.2021
Former [2021/50]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RO10.03.2021
RS10.03.2021
SE10.03.2021
SK10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
PT12.07.2021
Former [2021/48]AT10.03.2021
CZ10.03.2021
EE10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RS10.03.2021
SE10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/46]AT10.03.2021
FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RS10.03.2021
SE10.03.2021
SM10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/43]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
NL10.03.2021
RS10.03.2021
SE10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/38]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RS10.03.2021
SE10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/37]FI10.03.2021
HR10.03.2021
LT10.03.2021
LV10.03.2021
RS10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/36]FI10.03.2021
HR10.03.2021
LT10.03.2021
BG10.06.2021
NO10.06.2021
GR11.06.2021
Former [2021/35]FI10.03.2021
HR10.03.2021
LT10.03.2021
NO10.06.2021
Former [2021/33]FI10.03.2021
LT10.03.2021
NO10.06.2021
Cited inInternational search[XY]US6156758  (KUNG PEI-PEI [US], et al) [X] 4-6,17,18,21-24,27 * column 5, fourth compound; table 1, compound no. 16; * * abstract * * column 9, lines 52-64 * [Y] 1-27;
 [X]WO2009143058  (ALLERGAN INC [US], et al) [X] 1,3,4,6,7,10-13 * page 18, third row, first formula; page 28, compound 52; page 39, compound 86; page 40, compound 88; page 105, compound 217; page 106, compound 218; page 116, compound 52; page 119, compounds 86 and 88; page 132, compounds 217 and 218 *;
 [X]JP2000281660  ;
 [X]WO2005123697  (ASTELLAS PHARMA INC [JP], et al) [X] 1,4 * page 28, example 6 *;
 [X]WO2005082865  (YAMANOUCHI PHARMA CO LTD [JP], et al) [X] 4-6 * page 64, example 4; page 67, example 41; page 69, examples 69 and 72, page 73, examples 100 and 101 *;
 [X]WO2005046698  (SYNTA PHARMACEUTICALS CORP [US], et al) [X] 4 * example 9 *;
 [AD]WO2012005805  (GLAXOSMITHKLINE LLC [US], et al) [AD] 1-27 * claims 1,6-8 *;
 [AD]WO2011140324  (GLAXOSMITHKLINE LLC [US], et al) [AD] 1-27 * claims 1,11-13 *
 [XY]  - FENG LIU ET AL., "Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines", JOURNAL OF MEDICINAL CHEMISTRY, (2010), vol. 53, no. 15, doi:10.1021/jm100478y, ISSN 0022-2623, pages 5844 - 5857, XP002702498 [X] 1-6,11,12,18,20,27 * page 5844, abstract; page 5845, figure 1; page 5846, table 1, compounds 3a, 3l to 3n * [Y] 1-27

DOI:   http://dx.doi.org/10.1021/jm100478y
 [X]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2001, no. 10, Database accession no. 2001-084121, XP002702499 & JP2000281660 A 20001010 (SUMITOMO SEIYAKU KK) [X] 1-9,11-14 * abstract * * paragraph [0043], chemical formula 19 and table, entries 1 and 4; paragraph [0047], chemical formula 23 and table, entry 1 *
 [YD]  - FENG LIU ET AL., "Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines", JOURNAL OF MEDICINAL CHEMISTRY, (2011), vol. 54, no. 17, doi:10.1021/jm200903z, ISSN 0022-2623, pages 6139 - 6150, XP002702500 [YD] 1-27 * page 6139, abstract; page 6140, figure 1, compounds (1) and (5); figure 2; page 6141, table 1; scheme 1, compound 17; page 6142, table 2; page 6143, scheme 2; page 6144, tables 3 and 4 *

DOI:   http://dx.doi.org/10.1021/jm200903z
 [Y]  - FENG JIU ET AL., "Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a", JOURNAL OF MEDICINAL CHEMISTRY, (2009), vol. 52, no. 24, doi:10.1021/jm901543m, ISSN 0022-2623, pages 7950 - 7953, XP002702501 [Y] 1-27 * page 7950, figure 1; page 7951, tables 1, 2; page 7952, scheme 2 *

DOI:   http://dx.doi.org/10.1021/jm901543m
 [Y]  - CHANG Y ET AL, "Adding a Lysine Mimic in the Design of Potent Inhibitors of Histone Lysine Methyltransferases", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, vol. 400, no. 1, doi:10.1016/J.JMB.2010.04.048, ISSN 0022-2836, (20100702), pages 1 - 7, (20100609), XP027084528 [Y] 1-27 * page 1, abstract; page 2, figure 1 (a) *

DOI:   http://dx.doi.org/10.1016/j.jmb.2010.04.048
 [Y]  - STEFAN KUBICEK ET AL, "Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, vol. 25, no. 3, doi:10.1016/J.MOLCEL.2007.01.017, ISSN 1097-2765, (20070209), pages 473 - 481, (20070208), XP002635011 [Y] 1-27 * page 474, compound BIX-01294 *

DOI:   http://dx.doi.org/10.1016/J.MOLCEL.2007.01.017
ExaminationWO2009001060
    - C Zagni ET AL, "Histone Methyltransferase Inhibitors: Novel Epigenetic Agents for Cancer Treatment", Current Medicinal Chemistry, (20130101), pages 167 - 185, URL: http://docserver.ingentaconnect.com/deliver/connect/ben/09298673/v20n2/s2.pdf?expires=1487240098&id=89934347&titleid=3863&accname=European+Patent+Office&checksum=2166C033E1950F855D71EF569B566CE1, (20170216), XP055346532

DOI:   http://dx.doi.org/10.2174/092986713804806667
    - Daniel Decarlo ET AL, "Oncoepigenomics: Making histone lysine methylation count", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY., FR, (20120811), vol. 56, doi:10.1016/j.ejmech.2012.08.010, ISSN 0223-5234, pages 179 - 194, XP055346543

DOI:   http://dx.doi.org/10.1016/j.ejmech.2012.08.010
    - Philip Jones, "Development of second generation epigenetic agents", MedChemComm, United Kingdom, (20120101), vol. 3, no. 2, doi:10.1039/C1MD00199J, ISSN 2040-2503, pages 135 - 161, XP055285501

DOI:   http://dx.doi.org/10.1039/C1MD00199J
    - Munikumar R. Doddareddy ET AL, "Prospective Validation of a Comprehensive In silico hERG Model and its Applications to Commercial Compound and Drug Databases", ChemMedChem, DE, (20100427), vol. 5, no. 5, doi:10.1002/cmdc.201000024, ISSN 1860-7179, pages 716 - 729, XP055486904

DOI:   http://dx.doi.org/10.1002/cmdc.201000024
    - HORI ET AL, "Novel 4-Phenoxy-2- (1-piperazinyl)quinazolines as Potent Anticonvulsive and Antihypoxic Agents", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, (19900301), vol. 38, no. 3, ISSN 0009-2363, pages 681 - 687, XP002093298
    - KAZUHIRO YOKOYAMA ET AL, "Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 16, doi:10.1016/J.BMC.2008.05.036, ISSN 0968-0896, (20080715), pages 7021 - 7032, (20080520), XP002546278

DOI:   http://dx.doi.org/10.1016/J.BMC.2008.05.036
    - YOKOYAMA K ET AL, "Potent and orally bioavailable CCR4 antagonists: Synthesis and structure-activity relationship study of 2-aminoquinazolines", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 17, no. 1, doi:10.1016/J.BMC.2008.11.020, ISSN 0968-0896, (20090101), pages 64 - 73, (20081117), XP025875977

DOI:   http://dx.doi.org/10.1016/j.bmc.2008.11.020
by applicantWO2011140324
 WO2012005805
    - J. MED. CHEM., (2011), vol. 54, no. 17, pages 6139 - 6150
    - S. BYRN ET AL., PHARMACEUTICAL RESEARCH, (1995), vol. 12, no. 7, pages 954 - 954
    - R. LIU, Water-Insoluble Drug Formulation, CRC PRESS, page 553
    - T. HIGUCHI; V. STELLA, Prodrugs as Novel Delivery Systems, A. C. S. SYMPOSIUM SERIES, (1976), vol. 14
    - SHARMA S; KELLY TK; JONES PA, "Epigenetics in cancer", CARCINOGENESIS, (2010), vol. 31, pages 27 - 36
    - JONES PA; BAYLIN SB, "The fundamental role of epigenetic events in cancer.", NAT REV GENET, (2002), vol. 3, pages 415 - 28, XP008042555
    - KONDO Y; SHEN L; CHENG AS; AHMED S; BOUMBER Y; CHARO C ET AL., "Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation", NAT GENET, (2008), vol. 40, doi:doi:10.1038/ng.159, pages 741 - 50, XP002598429

DOI:   http://dx.doi.org/10.1038/ng.159
    - CHAPMAN-ROTHE N; BROWN R, "Approaches to target the genome and its epigenome in cancer", FUTURE MED CHEM, (2009), vol. 1, pages 1481 - 95
    - CAO R; ZHANG Y, "The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3", CURR OPIN GENET DEV, (2004), vol. 14, doi:doi:10.1016/j.gde.2004.02.001, pages 155 - 64, XP002364202

DOI:   http://dx.doi.org/10.1016/j.gde.2004.02.001
    - HANSEN KH; BRACKEN AP; PASINI D; DIETRICH N; GEHANI SS; MONRAD A ET AL., "A model for transmission of the H3K27me3 epigenetic mark", NAT CELL BIOL, (2008), vol. 10, doi:doi:10.1038/ncb1787, pages 1291 - 300, XP055403596

DOI:   http://dx.doi.org/10.1038/ncb1787
    - MARGUERON R; LI G; SARMA K; BLAIS A; ZAVADIL J; WOODCOCK CL ET AL., "Ezhl and Ezh2 maintain repressive chromatin through different mechanisms", MOL CELL, (2008), vol. 32, doi:doi:10.1016/j.molcel.2008.11.004, pages 503 - 18, XP055230106

DOI:   http://dx.doi.org/10.1016/j.molcel.2008.11.004
    - SHEN X; LIU Y; HSU YJ; FUJIWARA Y; KIM J; MAO X ET AL., "EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency", MOL CELL, (2008), vol. 32, pages 491 - 502
    - PIETERSEN AM; HORLINGS HM; HAUPTMANN M; LANGEROD A; AJOUAOU A; CORNELISSEN-STEIJGER P ET AL., "EZH2 and BMIl inversely correlate with prognosis and TP53 mutation in breast cancer", BREAST CANCER RES, (2008), vol. 10, doi:doi:10.1186/bcr2214, page R109, XP021053436

DOI:   http://dx.doi.org/10.1186/bcr2214
    - YU J; YU J; RHODES DR; TOMLINS SA; CAO X; CHEN G ET AL., "A polycomb repression signature in metastatic prostate cancer predicts cancer outcome", CANCER RES, (2007), vol. 67, doi:doi:10.1158/0008-5472.CAN-07-2498, pages 10657 - 63, XP055070110

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-07-2498
    - RAO ZY; CAI MY; YANG GF; HE LR; MAI SJ; HUA WF ET AL., "EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-betal and is a predictor of outcome in ovarian carcinoma patients", CARCINOGENESIS, (2010), vol. 31, pages 1576 - 83
    - LU C; HAN HD; MANGALA LS; ALI-FEHMI R; NEWTON CS; OZBUN L ET AL., "Regulation of tumor angiogenesis by EZH2", CANCER CELL, (2010), vol. 18, doi:doi:10.1016/j.ccr.2010.06.016, pages 185 - 97, XP055467227

DOI:   http://dx.doi.org/10.1016/j.ccr.2010.06.016
    - MIN J; ZASLAVSKY A; FEDELE G; MCLAUGHLIN SK; RECZEK EE; DE RT ET AL., "An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB", NAT MED, (2010), vol. 16, pages 286 - 94
    - FUSSBROICH B; WAGENERN; MACHER-GOEPPINGER S; BENNER A; FALTH M; SULTMANN H ET AL., "EZH2 depletion blocks the proliferation of colon cancer cells", PLOS ONE, (2011), vol. 6, page 21651
    - KAMMINGA LM; BYSTRYKH LV; DE BA; HOUWER S; DOUMA J; WEERSING E ET AL., "The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion", BLOOD, (2006), vol. 107, pages 2170 - 9
    - RIZZO S; HERSEY JM; MELLOR P; DAI W; SANTOS-SILVA A; LIBER D ET AL., "Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2", MOL CANCER THER, (2011), vol. 10, pages 325 - 35
    - TAN J; YANG X; ZHUANG L; JIANG X; CHEN W; LEE PL ET AL., "Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells", GENES DEV, (2007), vol. 21, doi:doi:10.1101/GAD.1524107, pages 1050 - 63, XP002585917

DOI:   http://dx.doi.org/10.1101/GAD.1524107
    - MIRANDA TB; CORTEZ CC; YOO CB; LIANG G; ABE M; KELLY TK ET AL., "DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation", MOL CANCER THER, (2009), vol. 8, doi:doi:10.1158/1535-7163.MCT-09-0013, pages 1579 - 88, XP055049435

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-09-0013
    - DAIGLE SR; OLHAVA EJ; THERKELSEN CA; MAJER CR; SNEERINGER CJ; SONG J ET AL., "Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor", CANCER CELL, (2011), vol. 20, doi:doi:10.1016/j.ccr.2011.06.009, pages 53 - 65, XP028379881

DOI:   http://dx.doi.org/10.1016/j.ccr.2011.06.009
    - YAO Y; CHEN P; DIAO J; CHENG G; DENG L; ANGLIN JL ET AL., "Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies", J AM CHEM SOC, (2011), vol. 133, doi:doi:10.1021/ja206312b, pages 16746 - 9, XP055096708

DOI:   http://dx.doi.org/10.1021/ja206312b
    - KUBICEK S; O'SULLIVAN RJ; AUGUST EM; HICKEY ER; ZHANG Q; TEODORO ML ET AL., "Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase", MOL CELL, (2007), vol. 25, doi:doi:10.1016/J.MOLCEL.2007.01.017, pages 473 - 81, XP002635011

DOI:   http://dx.doi.org/10.1016/J.MOLCEL.2007.01.017
    - SHI Y; DO JT; DESPONTS C; HAHM HS; SCHOLER HR; DING S, "A combined chemical and genetic approach for the generation of induced pluripotent stem cells", CELL STEM CELL, (2008), vol. 2, doi:doi:10.1016/j.stem.2008.05.011, pages 525 - 8, XP002564353

DOI:   http://dx.doi.org/10.1016/j.stem.2008.05.011
    - SHI Y; DESPONTS C; DO JT; HAHM HS; SCHOLER HR; DING S, "Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds", CELL STEM CELL, (2008), vol. 3, doi:doi:10.1016/j.stem.2008.10.004, pages 568 - 74, XP007913847

DOI:   http://dx.doi.org/10.1016/j.stem.2008.10.004
    - IMAI K; TOGAMI H; OKAMOTO T, "Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294", J BIOL CHEM, (2010), vol. 285, doi:doi:10.1074/jbc.M110.103531, pages 16538 - 45, XP002691444

DOI:   http://dx.doi.org/10.1074/jbc.M110.103531
    - LIU F; CHEN X; ALLALI-HASSANI A; QUINN AM; WASNEY GA; DONG A ET AL., "Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a", J MED CHEM, (2009), vol. 52, doi:doi:10.1021/jm901543m, pages 7950 - 3, XP002702501

DOI:   http://dx.doi.org/10.1021/jm901543m
    - LIU F; CHEN X; ALLALI-HASSANI A; QUINN AM; WIGLE TJ; WASNEY GA ET AL., "Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of2,4-diamino-7-aminoalkoxy-quinazolines", J MED CHEM, (2010), vol. 53, doi:doi:10.1021/jm100478y, pages 5844 - 57, XP002702498

DOI:   http://dx.doi.org/10.1021/jm100478y
    - LIU F; BARSYTE-LOVEJOY D; ALLALI-HASSANI A; HE Y; HEROLD JM; CHEN X ET AL., "Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines", J MED CHEM, (2011), vol. 54, doi:doi:10.1021/jm200903z, pages 6139 - 50, XP002702500

DOI:   http://dx.doi.org/10.1021/jm200903z
    - VEDADI M; BARSYTE-LOVEJOY D; LIU F; RIVAL-GERVIER S; ALLALI-HASSANI A; LABRIE V ET AL., "A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells", NAT CHEM BIOL, (2011), vol. 7, doi:doi:10.1038/nchembio.599, pages 566 - 74, XP002667515

DOI:   http://dx.doi.org/10.1038/nchembio.599
    - CHANG Y; ZHANG X; HORTON JR; UPADHYAY AK; SPANNHOFF A; LIU J ET AL., "Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294", NAT STRUCT MOL BIO, (2009), vol. 16, pages 312 - 7
    - WU H; CHEN X; XIONG J; LI Y; LI H; DING X ET AL., "Histone methyltransferase G9a contributes to H3K27 methylation in vivo", CELL RES, (2011), vol. 21, pages 365 - 7
    - PASINI D; BRACKEN AP; JENSEN MR; LAZZERINI DE; HELIN K, "Suzl2 is essential for mouse development and for EZH2 histone methyltransferase activity", EMBO J, (2004), vol. 23, pages 4061 - 71
    - SARMA K; MARGUERON R; IVANOV A; PIRROTTA V; REINBERG D, "Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo", MOL CELL BIO, (2008), vol. 28, pages 2718 - 31
    - WANG Z; ZANG C; ROSENFELD JA; SCHONES DE; BARSKI A; CUDDAPAH S ET AL., "Combinatorial patterns of histone acetylations and methylations in the human genome", NAT GENET, (2008), vol. 40, pages 897 - 903
    - BANNISTER AJ; KOUZARIDES T, "Regulation of chromatin by histone modifications", CELL RES, (2011), vol. 21, pages 381 - 95
    - RINGROSE L; PARO R, "Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins", ANNU REV GENET, (2004), vol. 38, pages 413 - 43
    - BARRADAS M; ANDERTON E; ACOSTA JC; LI S; BANITO A; RODRIGUEZ-NIEDENFUHR M ET AL., "Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS", GENES DEV, (2009), vol. 23, pages 1177 - 82
    - CHANG Y; GANESH T; HORTON JR; SPANNHOFF A; LIU J; SUN A ET AL., "Adding a lysine mimic in the design of potent inhibitors of histone lysine methyltransferases", J MOL BIOL, (2010), vol. 400, doi:doi:10.1016/j.jmb.2010.04.048, pages 1 - 7, XP027084528

DOI:   http://dx.doi.org/10.1016/j.jmb.2010.04.048
    - FOLETTA VC; WHITE LJ; LARSEN AE; LEGER B; RUSSELL AP, "The role and regulation of MAFbx/atrogin-1 and MuRFl in skeletal muscle atrophy", PFLUGERS ARCH, (2011), vol. 461, doi:doi:10.1007/s00424-010-0919-9, pages 325 - 35, XP019881385

DOI:   http://dx.doi.org/10.1007/s00424-010-0919-9
    - GREINER D; BONALDI T; ESKELAND R; ROEMER E; IMHOF A, "Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9", NAT CHEM BIO, (2005), vol. 1, doi:doi:10.1038/nchembio721, pages 143 - 5, XP055023658

DOI:   http://dx.doi.org/10.1038/nchembio721
    - CHOU JL; SU HY; CHEN LY; LIAO YP; HARTMAN-FREY C; LAI YH ET AL., "Promoter hypermethylation of FBX032, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer", LAB INVEST, (2010), vol. 90, pages 414 - 25
    - NELSON JD; DENISENKO 0; BOMSZTYK K, "Protocol for the fast chromatin immunoprecipitation (ChIP) method", NAT PROTOC, (2006), vol. 1, pages 179 - 85
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.